J

Researcher Profile

John F. Kurland

🏛 Oncology R&D, Late-Stage Development, AstraZeneca, Gaithersburg, MD

0000-0003-0863-2486

3

Publications

1,374

Citations

10

Co-Authors

2

Active Years

Publications

Journal Article New England Journal of Medicine Jul 17, 2025

Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer

Yelena Y. Janjigian · Salah-Eddin Al-Batran · Zev A. Wainberg · Kei Muro +23 more

10.1056/nejmoa2503701 164 citations

Open Access Journal Article Journal of Hepatology Oct 01, 2025

Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC

Lorenza Rimassa · Stephen L. Chan · Bruno Sangro · George Lau +23 more

10.1016/j.jhep.2025.03.033 91 citations

Journal Article NEJM Evidence Jul 26, 2022

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

Ghassan K. Abou-Alfa · George Lau · Masatoshi Kudo · Stephen L. Chan +27 more

10.1056/evidoa2100070 1,119 citations

Publication Timeline

2025

2

2022

1

Frequent Co-Authors

Alejandra Negro

Ghassan K. Abou-Alfa

Stephen L. Chan

Lorenza Rimassa

Yuriy Ostapenko

Wattana Sukeepaisarnjaroen